Journal of Forensic and Legal Medicine
Volume 14, Issue 2 , Pages 79-84 , February 2007

Peer review and the process of publishing of adverse drug event reports

Received 20 December 2005 ,Revised 18 January 2006 ,Accepted 10 February 2006.

References 

  1. DeBakey L, DeBakey S. The case report. I. Guidelines for preparation. Int J Cardiol. 1983;4(3):357–364
  2. Kelly W. The quality of published adverse event reports. Ann Pharmacother. 2003;37(12):1774–1778
  3. Isner JM, Estes NA, Thompson PD, et al. Acute cardiac events temporally related to cocaine abuse. New Engl J Med. 1986;315(23):1438–1443
  4. Hollingsworth JG, Lasker EG. The case against differential diagnosis: Daubert, medical causation testimony, and the scientific method. J Health Law. 2004;37(1):85–111
  5. Libman RB, Menna BL, Gulati S. Case report: consequences of ephedra use in an athlete. Lancet. 2005;366(Suppl. 1):S22
  6. Chen-Scarabelli C, Hughes SE, Landon G, et al. A case of fatal ephedra intake associated with lipofuscin accumulation, caspase activation and cleavage of myofibrillary proteins. Eur J Heart Fail. 2005;7(5):927–930
  7. Szakacs JE, Dimmette RM, Cowart EC. Pathologic implication of the catechol amines, epinephrine and norepinephrine. US Armed Forces Med J. 1959;10:908–925
  8. Szakacs JE, Cannon A. l-Norepinephrine myocarditis. Am J Clin Pathol. 1958;30(5):425–434
  9. Kuhl U, Pauschinger M, Bock T, et al. Parvovirus B19 infection mimicking acute myocardial infarction. Circulation. 2003;108(8):945–950
  10. Hardman J, Limbird L, Goodman A. Pharmacokinetics. In:  Wilkinson G editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 10th ed.. New York, Chicago, San Francisco, Lisbon, London, Madrid, Mexico City, Milan, New Selhi, San Juan Seoul, Singapore, Sydney, Toronto: McGraw-Hill Medical Publishing Division; 2001;p. 3–30
  11. Libman R, Menna B, Gulati S. Case report: consequences of ephedra use in an athlete. Lancet. 2005;366(Suppl. 1):S22
  12. Morgenstern LB, Viscoli CM, Kernan WN, et al. Use of Ephedra-containing products and risk for hemorrhagic stroke. Neurology. 2003;60(1):132–135
  13. Ariagno R, Karch SB, Middleberg R, Stephens BG, Valdes-Dapena M. Methamphetamine ingestion by a breast-feeding mother and her infant’s death: People v Henderson. JAMA. 1995;274(3):215
  14. Anon. Mother convicted for breast milk drug death of 3-month-old child. San Francisco Chronicle; 2003.
  15. Stewart JL, Meeker JE. Fetal and infant deaths associated with maternal methamphetamine abuse. J Anal Toxicol. 1997;21(6):515–517
  16. Anon . Patterns of medication use in the United States, 2004. Boston: Sloan Epidemiology Center, Boton University; 2004;
  17. Association AH. American Heart Association’s Heart Disease and Stroke Statistics – 2004 update. Dallas 2004.
  18. Wadman M. Journal grows suspicious of Vioxx data. Nature. 2005;438:899
  19. Curfman G, Morrissey S, Drazen J. Expression of concern: Bombardier et al., “Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis”. New Engl J Med. 2000;343:1520–1528NEJM. 2005;353:26
  20. Bradford-Hill A. The environment and disease: association or causation? President’s address. Proc Roy Soc Med. 1965;9:295–300
  21. Dryer O. Consultant struck off for fraudulent claims. BMJ. 2005;310:1554–1555
  22. White C. Suspected research fraud: difficulties of getting at the truth. BMJ. 2005;331(7511):281–288
  23. Hawthorne G, Irgens L, Lie R, et al. Retraction of paper on maternal diabetes. BMJ. 2003;327:7420–7429
  24. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. New Engl J Med. 2000;343(25):1833–1838
  25. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245

PII: S1353-1131(06)00049-6

doi: 10.1016/j.jcfm.2006.02.022

Journal of Forensic and Legal Medicine
Volume 14, Issue 2 , Pages 79-84 , February 2007